The CASP9 Knockout AGS Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout cell population in which the CASP9 gene has been disrupted in the AGS human gastric adenocarcinoma cell line. This polyclonal population provides a heterogeneous loss-of-function model for studying caspase-9-dependent signaling, offering researchers a genetically perturbed tool without the need for single-cell clonal isolation.
AGS is an adherent epithelial cell line derived from a human gastric adenocarcinoma. It is widely employed as a model system for gastric cancer biology, including investigations of tumor cell proliferation, invasion, and response to chemotherapeutic agents. The epithelial origin and cancer-associated genetic background make AGS cells particularly relevant for examining apoptosis regulation in gastrointestinal malignancies.
CASP9 encodes the initiator caspase-9, a critical component of the intrinsic apoptotic pathway. Under apoptotic stimuli, cytochrome c released from mitochondria binds APAF1, forming the apoptosome complex that recruits and activates caspase-9. Active caspase-9 subsequently cleaves and activates the executioner caspases, caspase-3 and caspase-7, leading to cellular demolition. Caspase-9 activity is tightly controlled by upstream regulators such as AKT, ERK, CDK1, and the inhibitor XIAP, and it interacts with molecular chaperones HSP60 and HSP90. The pathway also involves pro?apoptotic BAX and BAK and anti?apoptotic BCL?2 at the mitochondrial outer membrane.
In the AGS gastric cancer context, knockout of CASP9 eliminates functional caspase-9 protein, thus blocking apoptosome assembly and executioner caspase activation downstream of mitochondrial cytochrome c release. This genetic ablation impairs the cell’s ability to undergo apoptosis in response to intrinsic death signals, creating a valuable model for dissecting resistance mechanisms in gastric adenocarcinoma. The CASP9?null AGS polyclonal cells enable researchers to study how gastric cancer cells evade apoptosis during tumor progression and in response to therapy.
This knockout cell model is ideally suited for a broad range of apoptosis?focused applications. It can be used to screen for pro?apoptotic compounds that bypass caspase?9 dependence, to evaluate cancer drug resistance, or to model gastric cancer with defective mitochondrial cell death pathways. Representative assays include Western blotting for caspase?9 and cleaved caspase?3, luminescent caspase activity measurements, flow cytometry using annexin V/PI staining, TUNEL assays, cytochrome c release analysis, cell viability assays, and clonogenic survival studies. For further information or to discuss custom applications, please contact Ascent Research.
